explore -WSS

explore

author：explore 2025-09-29 21:27:59 - browse：8

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Hormonal contraceptives don’t actually treat endometriosis

WSS

Sanders wants to replace patents with prizes for drug inventions

David Liu startup to focus on CRISPR delivery

How the messy conversation about Dolly changed bioethics

How the messy conversation about Dolly changed bioethics

The unintended consequences of overturning Roe v. Wade

How a Boston hospital is priming medical residents to use GPT

focus

explore

explore

As demand for Covid shots wanes, Moderna seeks its next success

White House Covid adviser calls on docs to combat misinformation

Trump demands the U.S. pay no more for drugs than other countries … again

Dementia risk linked to living in disadvantaged areas: Study

Bright Health sells Medicare Advantage business to Molina

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Sports medicine is finally prioritizing gender equality

Patients, doctors press FTC to beef up hospital merger scrutiny

Apple is now the first public company to be valued at $3 trillion

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

Why the drug industry's warnings on the IRA's impact fall short

How the messy conversation about Dolly changed bioethics

Are infertility treatments 'essential' during the Covid

FDA panel to weigh safety of artificial wombs for preterm births

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

5 dead in mass shooting on Caribbean island of St. Vincent: Police

leisure time

hotspot

hotspot

focus